Clinical trials: Carcinoma;Endocrine
Ovarian Cancer
Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002477
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Pancreatic Carcinoma, Adjuvant Chemotherapy
Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo
Pancreatic carcinoma patients got benefit from adjuvant therapy after radical surgery. Gemcitabine combined with albumin-paclitaxel was recommended as the first-line regimen for adjuvant chemotherapy by NCCN guidelines.
- Conditions
- Pancreatic Carcinoma, Adjuvant Chemotherapy, Cancer-related Fatigue
- Trial name
- NCT05613465
- Testing
- Codonopsis
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Provincial People's Hospital
Breast Cancer, DCIS
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with…
- Trial name
- TAMENDOX (NCT03931928)
- Testing
- (Z)-Endoxifen supplementation according to genotype, (Z)-Endoxifen supplementation according to plasma levels
- Where
- 40 sites in Germany
- Volunteers
- 356 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
This is a phase 2 single-arm, open-label determining efficacy of Neo-adjuvant Abemaciclib and Fulvestrant in subjects with Hormone receptor positive patients with localized non-metastatic breast cancer who develop local…
- Trial name
- NCT04305236
- Testing
- Abemaciclib, Fulvestrant
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Irvine
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase I trial studies the side effects and the best dose of giving EGEN-001 together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal…
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma
- Trial name
- NCT01489371
- Testing
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Gynecologic Oncology Group
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer, Non-Small Cell Lung Cancer
A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy
The primary objective was to describe the incidence of febrile neutropenia based on granulocyte-colony stimulating factor (G-CSF) use (primary, secondary, treatment, or no usage) in patients receiving myelotoxic chemotherapy.
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT00883181
- Volunteers
- 1,370 people
- Sponsor
- Amgen
Bronchial Carcinoma, Esophageal Carcinoma
Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy
Evaluation of the impact of an activity tracker based fitness programme on the Qualitiy of Life after oncological therapy.
- Conditions
- Bronchial Carcinoma, Esophageal Carcinoma, Tumor of the Brain, Head and Neck Cancer
- Trial name
- OnkoFit II (NCT04517019)
- Testing
- Fitness tracker based activity training for Arm A and B. Booklet "physical training, exercise and cancer" and an introduction about physical activity during cancer therapy for Arm A, B, C
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- University Hospital Tuebingen
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03029598
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Washington
Ovarian Cancer, Neoplasms
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.
- Conditions
- Ovarian Cancer, Neoplasms, Carcinoma
- Trial name
- NCT00420381
- Testing
- enzastaurin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Carcinoma
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases
This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to…
- Trial name
- AntiCEA_CART (NCT03818165)
- Testing
- CAR2 Anti-CEA CAR-T cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sorrento Therapeutics, Inc.
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Ovarian Cancer
Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate.
- Trial name
- EPOCA (NCT07540403)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer
Clinically, there has been extensive experience with topotecan and cisplatin. Recently, several investigators have evaluated the combination of paclitaxel, cisplatin and topotecan.
- Trial name
- NCT00314678
- Testing
- Topotecan, Cisplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- John P. Fruehauf
Neoplasms, Neoplasms, Glandular and Epithelial
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic and…
- Conditions
- Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms
- Trial name
- NCT02897778
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with limited therapeutic options and a five-year survival rate below 10 % in advanced stages.
- Trial name
- ResCPa (NCT07153289)
- Testing
- CD318-CAR-T cells
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Colorectal Cancer, Pancreatic Cancer
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
- Trial name
- NCT07300150
- Testing
- PT0511, Cetuximab
- Where
- 9 sites in United States, South Korea
- Volunteers
- 210 people
- Sponsor
- PAQ Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.